A PHASE II RANDOMIZED CONTROLLED TRIAL OF NIVOLUMAB IN COMBINATION WITH BMS-986253 OR CABIRALIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS

Brief description of study

The purpose of this research study is to determine whether treatment with Cabiralizumab or HuMax-IL8 in combination with Nivolumab has additional benefit to Nivolumab treatment alone for treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.




Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.